Abstract Many small-molecule drugs accumulate in both host and gut microbial cells. Yet, the molecular consequences of intracellular drug accumulation are largely unknown. Here we show that the antidepressant duloxetine broadly disrupts RNA-protein interactions revealing a previously unrecognized mode of drug effect. Across phylogenetically diverse bacteria and human intestinal cells, duloxetine consistently reduced RNA-binding capacity, with approximately 80% of RNA-binding proteins responding to duloxetine in bacteria ( E. coli IAI1) and human (Caco-2) cells. As a mechanistic example, we show how duloxetine disrupts interactions between the pyrimidine biosynthesis enzyme PyrB and transcripts encoding metabolically linked functions. Biochemical and structural analyses show that duloxetine competes with aspartate, the natural substrate of PyrB, weakening the enzyme’s binding with 3′ UTR-localized stem-loop structures in its RNA partners. Overall, our results uncover the off-target disruption of RNA-protein interactions due to drug accumulation and have implications for understanding molecular basis of variation in drug efficacy and toxicity.

The gut microbiota is implicated in adverse effects associated with low-calorie sweeteners. Yet, the direct impact of sweeteners on gut bacteria remains largely uncharacterized. Here, we report interactions between 25 phylogenetically diverse gut bacterial strains and 39 commercially used sweeteners. We tested these sweeteners individually and in combination with four commonly co-consumed compounds, viz., advantame, caffeine, vanillin, and duloxetine. Three-quarters of the tested sweeteners individually impacted the growth of at least one tested bacterial strain. Further, over 100 interactions were found between sweeteners and the four co-consumed compounds. Isosteviol, a commonly used sweetener-component, and duloxetine, an antidepressant, synergistically inhibited Roseburia intestinalis, a bacterium previously linked to glucose homeostasis, and Parabacteroides merdae, a prevalent commensal linked to healthy microbiota. Proteomic, metabolomic, and genetic analyses indicate altered small molecule transport underpinning this sweetener-drug synergy. The isosteviol-duloxetine combination also modulated metabolism of a synthetic gut bacterial community, leading to increased toxicity to HeLa cells and altered secretion of inflammation-modulatory cytokines IL-6 and IL-8 by Caco-2 cells. Our data warrant further studies on interactions between low-calorie sweeteners and common xenobiotics.

Species in microbial communities need to stave off competition and capitalize on new resources that become available because of metabolic activities of others. However, intra-cellular molecular changes that underpin these responses are understudied, preventing mechanistic insights into community function and dynamics. Here we analyse proteomic and metabolomic responses in 104 pairwise co-cultures of 15 gut bacteria, spanning a diversity of ecological interactions from competition to mutualism. We find that molecular responses to co-culturing are substantial, with typically 50% of the quantified proteome changing in at least one co-culture, jointly influenced by genome size, species abundance and pH. Even closely related species and orthologue proteins show different expression profiles in response to the same partner, indicating functional diversification at both protein and species level. Small-molecule transport and carbon metabolism are among the most responsive processes, indicating pervasive metabolic interactions. Using metabolomics, we identify likely cross-fed metabolites, emergent polyamine metabolism and niche partitioning in amino acid utilization. Overall, our study uncovers how bacteria respond to the presence of other species through extensive remodelling of their proteome and metabolome.

Electron cryomicroscopy (cryo-EM) allows high spatial resolution visualization of biological specimens; however, it is challenging to chemically identify densities observed in cryo-EM. To overcome this, we combined cryo-EM with chemical imaging using focused ion beam secondary ion mass spectrometry (FIB-SIMS) for integrated spatiochemical analysis of untagged specimens. We show that our correlative workflow permits subcellular localization of molecules inside bacterial cells and is compatible with cryogenic light microscopy and FIB-milled lamellae of eukaryotic specimens. To highlight biological insights enabled by the workflow, we studied the uptake of bisphenol-AF, a widespread chemical pollutant, by environmental bacteria, revealing the storage of these chemicals within cytosolic phase-separated aggregates in pollutant-exposed cells, where they cannot be removed by the bacterial efflux machinery despite its robust upregulation. Cryo-EM-FIB-SIMS therefore represents an effective approach to map elemental and molecular signatures in near-native biological samples.

Abstract Microbial interactions unfold within environments structured by physical transport and chemical gradients. Yet most mechanistic studies rely on well-mixed systems that mask the reciprocal influences of environmental heterogeneity on metabolism and ecology. Here, we investigate how the physical environment modulates the interaction between the gut commensal Bacteroides thetaiotaomicron and Escherichia coli . In anoxic liquid culture, cell-resolved isotope imaging and genetic perturbations reveal exploitative cross-feeding, where E. coli consumes diffusible sugars released by B . thetaiotaomicron during starch degradation. When exposed to intestinal-like oxygen gradients in microfluidics, the interaction is restructured by spatial organization. The species self-organize into complementary niches: E. coli locally depletes sugars and oxygen, thereby expanding the anoxic niche required by B. thetaiotaomicron . A reactive transport model confirms that this organization arises from coupled feedback between physical transport and metabolic reaction rates. Together, our results reveal how physical structure and chemical gradients convert an exploitative cross-feeding interaction into a dynamic niche-construction process that generates emergent spatial organization and stabilizes coexistence.

Microbiology research is expanding from model species to non-model species and from studying single-species phenotypes to microbiomes and emergent functions. Here, we review the biotechnological opportunities brought forward by this expansion. Omics and automation have expanded the catalogue of non-model microbes that can be used in biotechnology, either on their own or as modules for assembling synthetic communities. The latter offer a complementary or alternative approach to monocultures due to their high resilience, single-step processing of complex substrates and suitability for open-environment applications. We also review the tools for engineering model and non-model microorganisms and communities, namely, targeted genome editing, adaptive laboratory evolution and ecological engineering. Going forward, increased focus on non-model microbes and methods for designing synthetic communities is needed to unlock the potential of the rich functional repertoire of non-model organisms and microbial communities.

Per- and polyfluoroalkyl substances (PFAS) are persistent pollutants that pose major environmental and health concerns. While few environmental bacteria have been reported to bind PFAS, the interaction of PFAS with human-associated gut bacteria is unclear. Here we report the bioaccumulation of PFAS by 38 gut bacterial strains ranging in concentration from nanomolar to 500 mu M. Bacteroides uniformis showed notable PFAS accumulation resulting in millimolar intracellular concentrations while retaining growth. In Escherichia coli, bioaccumulation increased in the absence of the TolC efflux pump, indicating active transmembrane transport. Cryogenic focused ion beam secondary-ion mass spectrometry confirmed intracellular localization of the PFAS perfluorononanoic acid (PFNA) in E. coli. Proteomic and metabolomic analysis of PFNA-treated cells, and the mutations identified following laboratory evolution, support these findings. Finally, mice colonized with human gut bacteria showed higher PFNA levels in excreted faeces than germ-free controls or those colonized with low-bioaccumulating bacteria. Together, our findings uncover the high PFAS bioaccumulation capacity of gut bacteria.

The gut microbiota is implicated in adverse effects associated with low-calorie sweeteners. Yet, the direct impact of sweeteners on gut bacteria remains largely uncharacterized. Here we report interactions between 25 phylogenetically diverse gut bacterial strains and 39 commercially used sweeteners. We tested these sweeteners individually and in combination with four commonly co-consumed compounds, viz., advantame, caffeine, vanillin, and duloxetine. Three quarters of the tested sweeteners individually impacted growth of at least one bacterial strain. Further, over 100 interactions were found between sweeteners and the four co-consumed compounds. Isosteviol, a commonly used sweetener, and duloxetine, an antidepressant, synergistically inhibited Roseburia intestinalis , a bacterium previously linked to glucose homeostasis, and Parabacteroides merdae , a prevalent commensal linked to healthy microbiota. Proteomic, metabolomic, and genetic analyses indicate altered small molecule transport underpinning this sweetener-drug synergy. The isosteviol-duloxetine combination also modulated metabolism of a synthetic gut bacterial community leading to increased toxicity to HeLa cells and altered secretion of inflammation modulatory cytokines IL-6 and IL-8 by Caco-2 cells. Together, our data bring forward the prevalence of interactions between low-calorie sweeteners and common xenobiotics. ### Competing Interest Statement The authors have declared no competing interest.

Species in microbial communities must respond to the presence of others to stave off resource competition or to capitalise on new resources that may become available due to additional metabolic activities. Such metabolic interactions manifest in growth effects such as competitive exclusion or cooperative growth boost. However, intra-cellular molecular changes that underpin these responses are very sparsely studied, preventing mechanistic insights into community function and dynamics. Here, we analyse meta-proteomics and metabolomic responses in 104 pairwise co-cultures of 15 diverse gut bacteria in a nutrient-rich medium. These co-cultures span a diversity of ecological interactions with competition, amensalism and exploitation being prominent, and with around one in five positive interactions. The species in co-cultures feature substantial molecular responses, with typically more than 60% of the proteome changing in response to at least one partner. Even closely related species and ortholog proteins show different expression profiles in response to the same partner indicating functional diversification at both protein and species level. We show that the magnitude of these responses is determined by genome size, species abundance, and pH. Small-molecule transport and carbon metabolism are among the most responsive processes indicating pervasive metabolic interactions. Using metabolomics, we identify likely cross-fed metabolites, emergent polyamine metabolism, and niche partitioning in amino acid utilisation. Overall, our study shows how bacteria respond to the presence of other species through extensive remodelling of their proteome and metabolome. ### Competing Interest Statement The authors have declared no competing interest. European Research Council, https://ror.org/0472cxd90, 866028 Medical Research Council, https://ror.org/03x94j517, MC\_UU\_00025/11 International Human Frontier Science Program Organization, https://ror.org/02ebx7v45, LT0018/2023 Swiss National Science Foundation, https://ror.org/00yjd3n13, P500PB_211100

Electrochemical approaches for monitoring cell barrier integrity have become important read-out tools for in vitro models. Conventional commercially available electrochemical devices are however poorly suited for monitoring the more complex and multi-dimensional models which have recently been developed thanks to advances in tissue engineering. In particular, commercially available devices are typically unable to provide barrier-by-barrier resolution in multi-barrier models. In this study, a gut-immune-vasculature model is presented and utilized to investigate the potential for a novel conformable device to independently monitor two cell barriers within the same model-device platform. The platform, supported by cytokine analysis, is first used to study known bacterial metabolites and dietary compounds, showing changes in epithelial and/or endothelial barrier resistance. The platform is also used to test complex mixtures of bacterial metabolites produced by four intestinal bacteria individually as well as by a community of 25 diverse gut bacteria. The study demonstrates the potential for employing tailored in vitro intestinal models coupled with novel electrochemical device monitoring for host-microbe interactions studies.

Industrial and agricultural chemicals such as pesticides are often considered to have restricted biological activity. Yet, there are concerns regarding their broader toxicity range and impact on human gut microbiota. Here we report a systematic in vitro screening to assess the impact of 1,076 pollutants, spanning diverse chemistries and indicated applications, on 22 prevalent gut bacteria. Our investigation uncovered 588 inhibitory interactions involving 168 chemicals, the majority of which were not previously reported to have antibacterial properties. Fungicides and industrial chemicals showed the largest impact, with around 30% exhibiting anti-gut-bacterial properties. We demonstrate that the scale of our dataset enables a machine learning approach for predicting the antibacterial activity of pesticides. Mechanistically, chemical-genetic screens using transposon mutant libraries of Parabacteroides merdae and Bacteroides thetaiotaomicron implicated genes involved in conserved efflux pathways, including the acrR locus, as mediators of pollutant resistance. We also found that loss-of-function mutations in genes coding for metabolic enzymes were selected under pollutant exposure, including those for branched short-chain fatty acid biosynthesis under tetrabromobisphenol A, a flame retardant. Taken together, our results suggest that the antibacterial activity of chemical pollutants should be considered in future studies on the microbiome and the emergence of antimicrobial resistance, as well as in toxicological assessments.

The human gut microbiome is a key contributor to health, and its perturbations are linked to many diseases. Small-molecule xenobiotics such as drugs, chemical pollutants and food additives can alter the microbiota composition and are now recognized as one of the main factors underlying microbiome diversity. Mapping the effects of such compounds on the gut microbiome is challenging because of the complexity of the community, anaerobic growth requirements of individual species and the large number of interactions that need to be quantitatively assessed. High-throughput screening setups offer a promising solution for probing the direct inhibitory effects of hundreds of xenobiotics on tens of anaerobic gut bacteria. When automated, such assays enable the cost-effective investigation of a wide range of compound-microbe combinations. We have developed an experimental setup and protocol that enables testing of up to 5,000 compounds on a target gut species under strict anaerobic conditions within 5 d. In addition, with minor modifications to the protocol, drug effects can be tested on microbial communities either assembled from isolates or obtained from stool samples. Experience in working in an anaerobic chamber, especially in performing delicate work with thick chamber gloves, is required for implementing this protocol. We anticipate that this protocol will accelerate the study of interactions between small molecules and the gut microbiome and provide a deeper understanding of this microbial ecosystem, which is intimately intertwined with human health.

A role for vitamin D in immune modulation and in cancer has been suggested. In this work, we report that mice with increased availability of vitamin D display greater immune-dependent resistance to transplantable cancers and augmented responses to checkpoint blockade immunotherapies. Similarly, in humans, vitamin D–induced genes correlate with improved responses to immune checkpoint inhibitor treatment as well as with immunity to cancer and increased overall survival. In mice, resistance is attributable to the activity of vitamin D on intestinal epithelial cells, which alters microbiome composition in favor of Bacteroides fragilis , which positively regulates cancer immunity. Our findings indicate a previously unappreciated connection between vitamin D, microbial commensal communities, and immune responses to cancer. Collectively, they highlight vitamin D levels as a potential determinant of cancer immunity and immunotherapy success.

Per- and polyfluoroalkyl Substances (PFAS) – the so-called ‘forever chemicals’ – are a major cause of environmental and health concern due to their toxicity and long-term persistence[1][1],[2][2]. Yet, no efficient mechanisms for their removal have been identified. Here we report bioaccumulation of PFAS by several gut bacterial species over a wide range of concentrations from nanomolar up to 500 μM. For bioaccumulating Bacteroides uniformis, a highly prevalent species, we estimate intracellular PFAS concentration in the mM range – above that of most native metabolites. Despite this high bioaccumulation, B. uniformis cells could grow appreciably up to 250 μM perfluorononanoic acid (PFNA) exposure. Escherichia coli, which accumulated PFAS to a much lesser extent, substantially increased PFAS bioaccumulation when lacking TolC efflux pump indicating trans-membrane transport in PFAS bioaccumulation. Electron microscopy and cryogenic Focused Ion Beam-Secondary Ion Mass-spectrometry revealed distinct morphological changes and intracellular localisation of PFNA aggregates. Bioaccumulation of PFAS and transmembrane transport is also evident in proteomics, metabolomics, thermal proteome profiling, and mutations following adaptive laboratory evolution. In an in vivo context, mice colonized with human gut bacteria showed, compared to germ-free controls or those colonized with low-bioaccumulating bacteria, higher PFNA levels in excreted feces. As the gut microbiota is a critical interface between exposure and human body, our results have implications for understanding and utilizing microbial contribution to PFAS clearance. ### Competing Interest Statement AEL and KRP are inventors in a patent application related to the findings presented in the manuscript (UK patent application nr. 2215307.6). AEL, JEDT and KRP are co-founders of Cambiotics ApS. [1]: #ref-1 [2]: #ref-2

Bidirectional interactions between the immune system and the gut microbiota are key contributors to various physiological functions. Immune-associated diseases such as cancer and autoimmunity, and efficacy of immunomodulatory therapies, have been linked to microbiome variation. Although COVID-19 infection has been shown to cause microbial dysbiosis, it remains understudied whether the inflammatory response associated with vaccination also impacts the microbiota. Here, we investigate the temporal impact of COVID-19 vaccination on the gut microbiome in healthy and immuno-compromised individuals; the latter included patients with primary immunodeficiency and cancer patients on immunomodulating therapies. We find that the gut microbiome remained remarkably stable post-vaccination irrespective of diverse immune status, vaccine response, and microbial composition spanned by the cohort. The stability is evident at all evaluated levels including diversity, phylum, species, and functional capacity. Our results indicate the resilience of the gut microbiome to host immune changes triggered by COVID-19 vaccination and suggest minimal, if any, impact on microbiome-mediated processes. These findings encourage vaccine acceptance, particularly when contrasted with the significant microbiome shifts observed during COVID-19 infection.

Contamination by industrial and agricultural chemicals like pesticides are a cause of great concern due to the risk to human and environmental health. While these chemicals are often considered to have restricted activity and are labelled as such, there are concerns over a broader toxicity range. Here we report the impact of 1076 pollutants spanning diverse chemistries and indicated applications on 22 prevalent commensal gut bacteria. Our systematic investigation uncovered 588 interactions involving 168 chemicals, the majority of which were not previously reported to have antibacterial properties. Fungicides and industrial chemicals showed the largest impact with circa 30% exhibiting anti-commensal properties. We find that the sensitivity to chemical pollutants across species surprisingly correlates with that to human-targeted drugs, suggesting common susceptibility mechanisms. Using a genome-wide chemical-genetic screen, we identified membrane transport and fatty acid metabolism as major modulators of the off-target toxicity of chemicals. Mutants exhibiting chemical resistance include those defective in producing human-health-relevant metabolites like branched short-chain fatty acids, indicating that chronic exposure could lead to selection against production of beneficial metabolites. Toxicokinetic modelling suggested gut bacteria could be used as more sensitive in vitro toxicity indicators for chemicals of concern than animal models. Together, our data uncovers the off-target activity of industrial and agricultural chemicals with widespread exposure against human gut bacteria. Impact on the structure and function of the microbiota should therefore be considered in assessing chemical safety. ### Competing Interest Statement KRP and AEL are co-founders of Cambiotics ApS

Synthetic communities can help uncover metabolic forces shaping microbial ecosystems. Yet, in case of the gut microbiota, culturing in undefined media has prevented detection of metabolic dependencies. Here we show, using chemically defined media, how species survival is jointly determined by supplied resources and community metabolism. We used 63 representative gut bacterial strains and varied inoculum compositions to assemble stable communities in 14 defined media. Over 95% of the species showed markedly improved or diminished performance relative to monoculture in at least one condition, including 153 cases (21%) of emergent survival, i.e., species incapable of surviving on their own but thriving in a community, and 252 (35%) community-driven extinctions. Through single species additions and exclusions, metabolomic analysis, and ecological modelling, we demonstrate how inter-species dependencies – especially in poor media – are mediated by biotic nutrient supply. Our results highlight communal metabolic dividend as a key biotic force promoting emergent survival and diversity. ### Competing Interest Statement KRP is co-founder of Cambiotics ApS. All other authors declare no competing interests.

Abstract Cheese fermentation and flavour formation are governed by complex biochemical reactions driven by polymicrobial activity. While the compositional dynamics of cheese microbiomes is relatively well mapped, the mechanistic role of microbial interactions in flavour formation is yet unknown. We microbially and metabolically characterised a year-long Cheddar cheese process using a commonly used starter culture containing Streptococcus thermophilus and Lactococcus strains. By using an experimental strategy whereby certain strains were left out from the starting mixture, we identified the critical role of S. thermophilus in boosting Lactococcus growth and in shaping flavour compound profile. Controlled milk fermentations with systematic exclusion of single Lactococcus strains, combined with genomics, genome-scale metabolic modelling, and metatranscriptomics, indicated that proteolytic activity of S. thermophilus relieves nitrogen limitation for Lactococcus and boosts de novo nucleotide biosynthesis. While S. thermophilus had large contribution to the flavour profile, L. cremoris also played a role by limiting diacetyl and acetoin formation which leads to off-flavour when in excess. This off-flavour control could be attributed to different metabolic re-routing of citrate between L. cremoris and other L. lactis strains. Further, closely related L. lactis strains exhibited different interaction patterns with S. thermophilus highlighting the importance of strain-specificity in cheese-making. Overall, our results bring forward the critical role of competitive and cooperative microbial interactions shaping cheese flavour profile.

Multi-omics analyses are increasingly employed in microbiome studies to obtain a holistic view of molecular changes occurring within microbial communities exposed to different conditions. However, it is not always clear to what extent each omics data type contributes to our understanding of the community dynamics and whether they are concordant with each other. Here we map the molecular response of a synthetic community of 32 human gut bacteria to three non-antibiotic drugs by using five omics layers, namely 16S rRNA gene profiling, metagenomics, metatranscriptomics, metaproteomics, and metabolomics. Using this controlled setting, we find that all omics methods with species resolution in their readouts are highly consistent in estimating relative species abundances across conditions. Furthermore, different omics methods complement each other in their ability to capture functional changes in response to the drug perturbations. For example, while nearly all omics data types captured that the antipsychotic drug chlorpromazine selectively inhibits Bacteroidota representatives in the community, the metatranscriptome and metaproteome suggested that the drug induces stress responses related to protein quality control and metabolomics revealed a decrease in polysaccharide uptake, likely caused by Bacteroidota depletion. Taken together, our study provides insights into how multi-omics datasets can be utilised to reveal complex molecular responses to external perturbations in microbial communities.

Cheese fermentation and flavour formation are the result of complex biochemical reactions driven by the activity of multiple microorganisms. Here, we studied the roles of microbial interactions in flavour formation in a year-long Cheddar cheese making process, using a commercial starter culture containing Streptococcus thermophilus and Lactococcus strains. By using an experimental strategy whereby certain strains were left out from the starter culture, we show that S. thermophilus has a crucial role in boosting Lactococcus growth and shaping flavour compound profile. Controlled milk fermentations with systematic exclusion of single Lactococcus strains, combined with genomics, genome-scale metabolic modelling, and metatranscriptomics, indicated that S. thermophilus proteolytic activity relieves nitrogen limitation for Lactococcus and boosts de novo nucleotide biosynthesis. While S. thermophilus had large contribution to the flavour profile, Lactococcus cremoris also played a role by limiting diacetyl and acetoin formation, which otherwise results in an off-flavour when in excess. This off-flavour control could be attributed to the metabolic re-routing of citrate by L. cremoris from diacetyl and acetoin towards α -ketoglutarate. Further, closely related Lactococcus lactis strains exhibited different interaction patterns with S. thermophilus , highlighting the significance of strain specificity in cheese making. Our results highlight the crucial roles of competitive and cooperative microbial interactions in shaping cheese flavour profile.